Table 1.
Baseline Patients’ Characteristics
| TANGO Group, n = 145 | Non-TANGO Group, n = 412 | P Value | |
|---|---|---|---|
| Age, years, median (IQR) | 49 (40–55) | 53 (47–58) | <.001 |
| Male sex, n (%) | 111 (76.6) | 281 (68.2) | .058 |
| Ethnicity, n (%) | |||
| Caucasians | 129 (89.0) | 384 (93.2) | .112 |
| Sub-Saharan | 4 (2.8) | 14 (3.4) | |
| Central or South American | 6 (4.1) | 6 (1.5) | |
| Other/unknown | 6 (4.1) | 8 (1.9) | |
| Risk factor for HIV, n (%) | |||
| Heterosexual | 56 (38.6) | 169 (41.0) | <.001 |
| MSM | 37 (25.5) | 108 (26.2) | |
| IDU | 15 (10.4) | 86 (20.9) | |
| Other/unknown | 37 (25.5) | 49 (11.9) | |
| CDC stage C, n (%) | 20 (13.8) | 62 (15.0) | .854 |
| Anti HCV–positive serostatus, n (%) | 25 (17.2) | 101 (24.5) | .076 |
| Peak HIV RNA, log10 copies/mL, median (IQR) | 4.95 (4.45–5.35) | 4.89 (4.37–5.43) | .780 |
| Nadir CD4+ cell count, cells/mm3, median (IQR) | 278 (140–395) | 212 (93–309) | .001 |
| Non-B HIV subtype, n (%) | 5 (3.4) | 13 (3.2) | .875 |
| Years from HIV diagnosis, median (IQR) | 9 (5–17) | 18 (10–24) | <.001 |
| Years of cumulative ARV exposure, median (IQR) | 7 (3–12) | 13 (8–19) | <.001 |
| Months of virological suppression, median (IQR) | 61.5 (31.5–103.1) | 95.4 (51.5–126.9) | <.001 |
| Time of virological suppression ≤6 months (%) | / | 13 (3.2) | NA |
| Baseline CD4+ cell count, cells/mm3, median (IQR) | 692 (453–912) | 660 (500–876) | .826 |
| Previous virological failure, n (%) | / | 223 (54.1) | NA |
| Previous ARV regimen, n (%) | |||
| 2NRTI + bPI | 22 (15.2) | 55 (13.3) | <.001 |
| 2NRTI + NNRTI | 90 (62.1) | 55 (13.3) | |
| 2NRTI + INI | 33 (22.7) | 57 (13.8) | |
| Dual/monotherapy | 0 (0) | 220 (53.4) | |
| Other | 0 (0) | 25 (6.2) | |
| M184V resistance mutation detection at last genotipic resistance test, n (%) | / | 45 (10.9) | NA |
| Reason for starting DTG + 3TC, n (%): | |||
| Simplification/proactive switch | 49 (33.8) | 106 (25.7) | <.001 |
| Dyslipidemia | 5 (3.4) | 87 (21.1) | |
| Toxicity GI tract | 13 (9.0) | 31 (7.5) | |
| Renal toxicity | 13 (9.0) | 18 (4.4) | |
| Osteopenia/osteoporosis | 20 (13.8) | 7 (1.7) | |
| Other toxicity | 10 (6.8) | 10 (2.4) | |
| Drug-drug interaction | 6 (4.1) | 30 (7.3) | |
| Other/unknown | 29 (20.1) | 123 (29.9) |
Abbreviations: 3TC, lamivudine; ARV, antiretroviral; bPI, boosted-protease inhibitor; CDC, Centers for Disease Control and Prevention; DTG, dolutegravir; GI, gastrointestinal; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, intravenous drug users; INI, integrase inhibitor; IQR, interquartile range; MSM, men who have sex with men; NA, not applicable; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.